tegafur has been researched along with Body Weight in 43 studies
Body Weight: The mass or quantity of heaviness of an individual. It is expressed by units of pounds or kilograms.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Tegafur was effective, but levamisole with or without tegafur was not effective against early cancer." | 5.27 | Longer survival and fewer metastases by levamisole and tegafur in 1, 2-dimethylhydrazine-induced murine colonic cancers. ( Aoki, N; Hamada, S; Hirayama, R; Matsumura, J; Mishima, Y; Miyanaga, T; Takagi, Y, 1985) |
| "5 mg/kg/day regimen produced one dead or moribund dog of each sex; black-brown patch (melanin deposition) and inflammatory changes in the eyes and skin; decreased in body weight gains; increases in MCV, MCH, monocyte ratio, and serum protein and uric acid; decreases in lymphocyte ratio and erythrocyte count, hematocrit, hemoglobin, albumin, A/G ratio, cholesterol (esterified, total and free), phospholipids, triglycerides, cholinesterase activity and creatinine; increases in relative liver and adrenal weights." | 3.69 | [A 52-week oral toxicity study of a new antineoplastic agent S-1 in dogs]. ( Enomoto, M; Inoue, H; Kitajima, S; Kobayashi, K; Okamura, T; Watari, N; Yamaguchi, S, 1996) |
| "Patients with advanced gastric cancer were randomly divided into two groups: with or without ubenimex." | 2.76 | Ubenimex capsule improves general performance and chemotherapy related toxicity in advanced gastric cancer cases. ( Huang, XE; Huo, JG; Li, CG; Li, Y; Xu, JW, 2011) |
| " Furthermore, the survival was elevated in proportion to the increase of total dosage of futraful." | 2.65 | [Effect of postoperative long-term chemotherapy of stomach cancer using mitomycin C and futraful--the secondary study (1)]. ( Abe, O; Akiyama, H; Hattori, T; Hayasaka, A; Inokuchi, K; Inoue, K; Ito, I; Kasai, Y; Kikuchi, K; Kondo, T; Muto, T; Nakajima, T; Sugie, S; Taguchi, T, 1982) |
| "However, the sensitivity to the micrometastases was high." | 1.31 | Experimental postoperative adjuvant chemotherapy by UFT using primary tumor amputation model. ( Fujioka, A; Fukushima, M; Nakano, K; Okabe, H; Saito, H; Sato, K; Takechi, T; Takeda, S; Uchida, J; Unemi, N, 2000) |
| "The effects of 1-(2-tetrahydrofuryl)-5-fluorouracil in combination with uracil (UFT) on mammary carcinogenesis and growth of tumors induced with 7,12-dimethylbenz[a]anthracene (DMBA) were investigated in rats." | 1.29 | 1-(2-Tetrahydrofuryl)-5-fluorouracil in combination with uracil suppresses mammary carcinogenesis and growth of tumors induced with 7,12-dimethylbenz[a]anthracene in rats. ( Kudo, H; Maemura, M; Mitamura, T; Nakayama, T; Sakamoto, S; Sassa, S; Suzuki, S; Yoshimura, S, 1996) |
| " In the CDHP and Oxo treatment groups of rats, the only toxic signs were soft or diarrheal stools on the dosing day." | 1.29 | [Oral single-dose toxicity study of a new antineoplastic agent S-1, and its components, CDHP, and Oxo]. ( Hayashi, T; Hirota, T; Irimura, K; Ohmae, S; Tanaka, G, 1996) |
| " No adverse effects of S-1 on the length of gestation, gestation index, delivery and nursing ability were found." | 1.29 | [Reproductive and developmental toxicity study of a new antineoplastic agent, S-1 (IV)--Perinatal and postnatal study in rats by oral administration]. ( Fujimura, T; Furuhashi, T; Kato, M; Koida, M, 1996) |
| "Decreased body weight was observed in mice treated with 5-FU and UFT but not in those treated with S-1." | 1.29 | [Immunotoxic effects of a new antineoplastic agent S-1 in mice--comparison with S-1, UFT and 5-FU]. ( Kouchi, Y; Maeda, Y; Morinaga, H; Ohuchida, A, 1996) |
| " The bioavailability of UK-21 given p." | 1.28 | Antitumor activity of two novel low immunosuppressive fluoropyrimidines UK-21 and UK-25. ( Kato, T; Kitaichi, K; Koda, A; Mori, H; Sakamoto, O, 1992) |
| "Tegafur was administered for 24 weeks at respective doses of 90 mg, 120 mg and 150 mg/kg/day." | 1.27 | [Maximum tolerated dose of tegafur in rats]. ( Aoki, N; Hamada, S; Hirayama, R; Matsumura, J; Mishima, Y; Miyanaga, T; Takagi, Y, 1984) |
| " 5'-DFUR was less toxic to immune organs and the functions than those by other fluorinated pyrimidines." | 1.27 | [Antitumor activity and toxicity to the immune system and intestine, of the fluorinated pyrimidines FUra, 5'-DFUR, tegafur and UFT]. ( Fujimoto, K; Ishitsuka, H; Matsuura, N; Miwa, M; Ninomiya, Y; Ryu, M, 1988) |
| "A chemosensitivity test for UFT and FT-207, which are used in long-term administration clinically, was investigated for prediction of clinical response." | 1.27 | [In vivo chemosensitivity test for UFT and FT-207. I--Subrenal capsule assay]. ( Hattori, T; Hirabayashi, N; Niimi, K; Niimoto, M; Nishiyama, M; Nosoh, Y; Tohge, T; Yamaguchi, M, 1987) |
| "Nine canine subjects confirmed to have gastric cancers by punch biopsy under gastrofiberscopy were divided into 3 group given 5 mg/kg/day of UFT for 101 days, 7." | 1.27 | [UFT therapy of experimental gastric cancer in beagles induced by ENNG]. ( Ichiki, H; Izumi, T; Kurihara, M; Miyasaka, K; Orima, H; Sasaki, Y; Tasaka, K, 1987) |
| "Tegafur was effective, but levamisole with or without tegafur was not effective against early cancer." | 1.27 | Longer survival and fewer metastases by levamisole and tegafur in 1, 2-dimethylhydrazine-induced murine colonic cancers. ( Aoki, N; Hamada, S; Hirayama, R; Matsumura, J; Mishima, Y; Miyanaga, T; Takagi, Y, 1985) |
| "Urinary bladder tumors were induced in 18 of 20 rats (90." | 1.26 | [Effect of FT-207 on bladder cancer in rats induced by BBN. II: The effect of oral administration of FT-207 during oncogenesis of bladder cancer]. ( Babaya, K; Hiramatsu, T; Hirao, Y; Ijuin, M; Kihoin, K; Maruyama, Y; Ohara, S; Okajima, E; Tanaka, M, 1982) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 13 (30.23) | 18.7374 |
| 1990's | 22 (51.16) | 18.2507 |
| 2000's | 6 (13.95) | 29.6817 |
| 2010's | 2 (4.65) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Aoyama, T | 1 |
| Kawabe, T | 1 |
| Fujikawa, H | 1 |
| Hayashi, T | 7 |
| Yamada, T | 1 |
| Tsuchida, K | 1 |
| Yukawa, N | 1 |
| Oshima, T | 1 |
| Rino, Y | 1 |
| Masuda, M | 1 |
| Ogata, T | 1 |
| Cho, H | 1 |
| Yoshikawa, T | 1 |
| Xu, JW | 1 |
| Li, CG | 1 |
| Huang, XE | 1 |
| Li, Y | 1 |
| Huo, JG | 1 |
| Mori, T | 2 |
| Fujiwara, Y | 1 |
| Yano, M | 1 |
| Tamura, S | 1 |
| Yasuda, T | 1 |
| Takiguchi, S | 1 |
| Monden, M | 1 |
| Yurimoto, S | 1 |
| Miyakawa, A | 1 |
| Okuzawa, A | 1 |
| Sakamoto, S | 3 |
| Sakamoto, K | 1 |
| Hosoda, S | 1 |
| Kamano, T | 1 |
| Moriyama, K | 1 |
| Kouchi, Y | 2 |
| Morinaga, H | 2 |
| Irimura, K | 2 |
| Ohuchida, A | 2 |
| Goto, T | 1 |
| Yoshizawa, Y | 1 |
| Hirayama, R | 2 |
| Hamada, S | 2 |
| Matsumura, J | 2 |
| Takagi, Y | 2 |
| Miyanaga, T | 2 |
| Aoki, N | 2 |
| Mishima, Y | 2 |
| Okajima, E | 1 |
| Hiramatsu, T | 1 |
| Kihoin, K | 1 |
| Ijuin, M | 1 |
| Hirao, Y | 1 |
| Ohara, S | 1 |
| Babaya, K | 1 |
| Tanaka, M | 1 |
| Maruyama, Y | 1 |
| Kasai, Y | 1 |
| Inokuchi, K | 1 |
| Hattori, T | 3 |
| Inoue, K | 1 |
| Taguchi, T | 2 |
| Kondo, T | 1 |
| Akiyama, H | 1 |
| Abe, O | 1 |
| Ito, I | 1 |
| Nakajima, T | 1 |
| Muto, T | 1 |
| Kikuchi, K | 1 |
| Sugie, S | 1 |
| Hayasaka, A | 1 |
| Nukatsuka, M | 1 |
| Fujioka, A | 2 |
| Saito, H | 4 |
| Nakano, K | 4 |
| Uchida, J | 4 |
| Oh-ie, S | 1 |
| Nomura, N | 1 |
| Takeda, S | 4 |
| Unemi, N | 3 |
| Ishitani, K | 1 |
| Mizuno, M | 1 |
| Kudo, H | 2 |
| Suzuki, S | 2 |
| Kasahara, N | 1 |
| Sugiura, Y | 1 |
| Nagasawa, H | 1 |
| Fujita, F | 1 |
| Fujita, M | 1 |
| Inaba, H | 1 |
| Uchida, K | 1 |
| Nishijima, Y | 2 |
| Kasaya, T | 1 |
| Akaza, H | 1 |
| Koiso, K | 2 |
| Nemoto, R | 2 |
| Harada, M | 1 |
| Takechi, T | 3 |
| Sassa, S | 1 |
| Yoshimura, S | 1 |
| Nakayama, T | 1 |
| Maemura, M | 1 |
| Mitamura, T | 1 |
| Satake, H | 1 |
| Fukushima, M | 2 |
| Tanaka, G | 3 |
| Hirota, T | 2 |
| Ohmae, S | 3 |
| Hasegawa, H | 1 |
| Hakoi, K | 1 |
| Besshi, K | 1 |
| Yamaguchi, S | 3 |
| Kito, S | 1 |
| Kurokawa, K | 2 |
| Kitajima, S | 1 |
| Okamura, T | 1 |
| Kobayashi, K | 1 |
| Watari, N | 1 |
| Inoue, H | 1 |
| Enomoto, M | 1 |
| Shinomiya, M | 3 |
| Imamura, K | 1 |
| Izumi, K | 1 |
| Yukiyama, S | 2 |
| Ikebuchi, K | 2 |
| Sato, T | 1 |
| Furuhashi, T | 1 |
| Kato, M | 1 |
| Fujimura, T | 1 |
| Koida, M | 1 |
| Maeda, Y | 1 |
| Tazawa, K | 1 |
| Sakamoto, T | 1 |
| Kuroki, Y | 1 |
| Yamashita, I | 1 |
| Okamoto, M | 1 |
| Katuyama, S | 1 |
| Fujimaki, M | 1 |
| Cao, S | 1 |
| Frank, C | 1 |
| Shirasaka, T | 2 |
| Rustum, YM | 1 |
| Sato, K | 1 |
| Okabe, H | 1 |
| Kitamura, M | 1 |
| Arai, K | 1 |
| Iwasaki, Y | 1 |
| Takahashi, T | 1 |
| Saitoh, K | 1 |
| Fujii, T | 1 |
| Yoshisue, K | 1 |
| Hironaga, K | 1 |
| Yamamoto, A | 1 |
| Nagayama, S | 1 |
| Kawaguchi, Y | 1 |
| Pallavicini, MG | 1 |
| Cohen, AM | 1 |
| Dethlefsen, LA | 1 |
| Gray, JW | 1 |
| Hortobagyi, GN | 1 |
| Blumenschein, GR | 1 |
| Tashima, CK | 1 |
| Buzdar, AU | 1 |
| Burgess, MA | 1 |
| Livingston, RB | 1 |
| Valdivieso, M | 1 |
| Gutterman, JU | 1 |
| Hersh, EM | 1 |
| Bodey, GP | 1 |
| Sakamoto, O | 1 |
| Mori, H | 1 |
| Kitaichi, K | 1 |
| Koda, A | 1 |
| Kato, T | 1 |
| Hinotsu, S | 1 |
| Takahashi, Y | 1 |
| Ohta, T | 1 |
| Ooi, A | 1 |
| Ogino, T | 1 |
| Mai, M | 1 |
| Ninomiya, Y | 1 |
| Ryu, M | 1 |
| Matsuura, N | 1 |
| Fujimoto, K | 1 |
| Miwa, M | 1 |
| Ishitsuka, H | 1 |
| Nishiyama, M | 2 |
| Takagami, S | 1 |
| Kirihara, Y | 1 |
| Saeki, T | 1 |
| Hirabayashi, N | 2 |
| Nosoh, Y | 2 |
| Niimoto, M | 2 |
| Kagawa, S | 1 |
| Takigawa, H | 1 |
| Aga, Y | 1 |
| Niimi, K | 1 |
| Yamaguchi, M | 1 |
| Tohge, T | 1 |
| Kurihara, M | 1 |
| Izumi, T | 1 |
| Ichiki, H | 1 |
| Tasaka, K | 1 |
| Orima, H | 1 |
| Miyasaka, K | 1 |
| Sasaki, Y | 1 |
| Yamada, K | 1 |
| Takao, S | 1 |
| Ishizawa, T | 1 |
| Shimazu, H | 1 |
| Hozawa, J | 1 |
| Mori, I | 1 |
| Matsubara, A | 1 |
| Tanita, J | 1 |
| Fujita, S | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase I, Open-Label, Non-Randomized, Dose-Escalating Safety, Tolerability and Pharmacokinetic Study of TAS-114 in Combination With S-1 in Patients With Advanced Solid Tumors[NCT02454062] | Phase 1 | 120 participants (Actual) | Interventional | 2013-03-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 trials available for tegafur and Body Weight
| Article | Year |
|---|---|
Ubenimex capsule improves general performance and chemotherapy related toxicity in advanced gastric cancer cases.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Blood Platelets; Body Weigh | 2011 |
[Effect of postoperative long-term chemotherapy of stomach cancer using mitomycin C and futraful--the secondary study (1)].
Topics: Aged; Antibiotics, Antineoplastic; Blood Cell Count; Body Weight; Clinical Trials as Topic; Drug The | 1982 |
41 other studies available for tegafur and Body Weight
| Article | Year |
|---|---|
Loss of Lean Body Mass as an Independent Risk Factor for Continuation of S-1 Adjuvant Chemotherapy for Gastric Cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Body Composition; B | 2015 |
Experimental study to evaluate the usefulness of S-1 in a model of peritoneal dissemination of gastric cancer.
Topics: Animals; Antimetabolites, Antineoplastic; Body Weight; Disease Models, Animal; Drug Combinations; Ea | 2003 |
Enhancement of the anti-tumor activity of S-1 by low-dose cisplatin in mice bearing the sarcoma-180 model.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Body Weight; Cisplatin; Drug Combinations; | 2005 |
Diamine oxidase, a plasma biomarker in rats to GI tract toxicity of oral fluorouracil anti-cancer drugs.
Topics: Administration, Oral; Amine Oxidase (Copper-Containing); Animals; Antimetabolites, Antineoplastic; A | 2006 |
[Maximum tolerated dose of tegafur in rats].
Topics: Administration, Oral; Animals; Body Weight; Drug Administration Schedule; Drug Tolerance; Fluorourac | 1984 |
[Effect of FT-207 on bladder cancer in rats induced by BBN. II: The effect of oral administration of FT-207 during oncogenesis of bladder cancer].
Topics: Administration, Oral; Animals; Antineoplastic Agents; Body Weight; Butylhydroxybutylnitrosamine; Flu | 1982 |
[Antitumor and anticachectic activity of UFT in BALB/c mice bearing colon 26 adenocarcinoma].
Topics: Adenocarcinoma; Animals; Antineoplastic Combined Chemotherapy Protocols; Body Weight; Cachexia; Colo | 1994 |
Suppression of mammary tumors by oral administration of 1-(2-tetrahydrofuryl)-5-fluorouracil in combination with uracil in SHN virgin mice.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Body Weight; Female; Fluorouracil; Mammary | 1993 |
[Antitumor activity of BOF-A2, a new 5-fluorouracil derivative, against human cancers xenografted in nude mice by intermittent administration].
Topics: Administration, Oral; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols | 1993 |
[Subrenal capsule assay of nude mice for testing the effectiveness of UFT for rat prostatic carcinoma (R3327)].
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Body Weight; Cisplatin; Male; Mice; Mice, I | 1993 |
[Experimental study on the combined treatment of UFT with etoposide against mouse Lewis lung carcinoma].
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Body Weight; DNA, Neoplasm; Etoposide; Lung | 1993 |
1-(2-Tetrahydrofuryl)-5-fluorouracil in combination with uracil suppresses mammary carcinogenesis and growth of tumors induced with 7,12-dimethylbenz[a]anthracene in rats.
Topics: 9,10-Dimethyl-1,2-benzanthracene; Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined | 1996 |
[Antimetastatic effects of UFT on murine liver metastasis model using L5178YHM lymphoma].
Topics: Animals; Body Weight; Drug Combinations; Floxuridine; Leukemia L5178; Liver Neoplasms; Male; Mice; T | 1996 |
[Oral single-dose toxicity study of a new antineoplastic agent S-1, and its components, CDHP, and Oxo].
Topics: Administration, Oral; Alopecia; Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Ch | 1996 |
[A 13-week oral repeated dose toxicity study of a new antineoplastic agent S-1 in rats].
Topics: Administration, Oral; Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy | 1996 |
[A 26-week oral repeated dose toxicity study of a new antineoplastic agent S-1 in rats].
Topics: Administration, Oral; Animals; Antimetabolites, Antineoplastic; Blood Chemical Analysis; Body Weight | 1996 |
[An oral repeated dose toxicity study of a new antineoplastic agent S-1 in dogs. I. A 13-week repeated dose toxicity study. II. An ophthalmologic toxicity recovery study].
Topics: Administration, Oral; Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy | 1996 |
[A 52-week oral toxicity study of a new antineoplastic agent S-1 in dogs].
Topics: Administration, Oral; Animals; Antimetabolites, Antineoplastic; Blood Chemical Analysis; Blood Coagu | 1996 |
[Reproductive and developmental toxicity study of a new antineoplastic agent, S-1 (I)--Fertility study in rats by oral administration].
Topics: Abnormalities, Drug-Induced; Administration, Oral; Animals; Antimetabolites, Antineoplastic; Body We | 1996 |
[Reproductive and developmental toxicity study of a new antineoplastic agent, S-1 (II)--Teratological study in rats by oral administration].
Topics: Abnormalities, Drug-Induced; Administration, Oral; Animals; Animals, Newborn; Antimetabolites, Antin | 1996 |
[Reproductive and developmental toxicity study of a new antineoplastic agent, S-1 (IV)--Perinatal and postnatal study in rats by oral administration].
Topics: Administration, Oral; Animals; Animals, Newborn; Antimetabolites, Antineoplastic; Behavior, Animal; | 1996 |
[Reproductive and developmental toxicity study of a new antineoplastic agent, S-1 (III)--Teratological study in rabbits by oral administration].
Topics: Abnormalities, Drug-Induced; Administration, Oral; Animals; Antimetabolites, Antineoplastic; Body We | 1996 |
[Immunotoxic effects of a new antineoplastic agent S-1 in mice--comparison with S-1, UFT and 5-FU].
Topics: Animals; Antibody Formation; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 1996 |
Inhibitory effects of fluorinated pyrimidines, 5'-DFUR, UFT and T-506, in a model of hepatic metastasis of mouse colon 26 adenocarcinoma-assessment of inhibitory activity and adverse reactions at the maximum tolerated dose.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Body Weight; Colonic Neoplasms; Dose-Response Relati | 1997 |
5-Fluorouracil prodrug: role of anabolic and catabolic pathway modulation in therapy of colorectal cancer.
Topics: Animals; Body Weight; Colorectal Neoplasms; Female; Fluorouracil; Leucovorin; Metabolic Clearance Ra | 1995 |
Experimental postoperative adjuvant chemotherapy by UFT using primary tumor amputation model.
Topics: Amputation, Surgical; Animals; Antineoplastic Combined Chemotherapy Protocols; Body Weight; Carcinom | 2000 |
[Combined effect of S-1 and CDDP as a modulator for colon 26 liver metastasis].
Topics: Animals; Antimetabolites, Antineoplastic; Body Weight; Cisplatin; Colonic Neoplasms; Drug Combinatio | 2000 |
Reduction of 5-fluorouracil (5-FU) gastrointestinal (GI) toxicity resulting from the protection of thymidylate synthase (TS) in GI tissue by repeated simultaneous administration of potassium oxonate (Oxo) in rats.
Topics: Animals; Antimetabolites, Antineoplastic; Body Weight; Colon; Diarrhea; Digestive System; Drug Combi | 2000 |
In vivo effects of 5-fluorouracil and ftorafur[1-(tetrahydrofuran-2-yl)-5-fluorouracil] on murine mammary tumors and small intestine.
Topics: Animals; Body Weight; Cell Division; DNA; Female; Fluorouracil; Intestine, Small; Male; Mammary Neop | 1979 |
Ftorafur, adriamycin, cyclophosphamide and BCG in the treatment of metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Agents; BCG Vaccine; Body Weight; Breast Neoplasms; Central Nervous Syst | 1979 |
Antitumor activity of two novel low immunosuppressive fluoropyrimidines UK-21 and UK-25.
Topics: Administration, Oral; Animals; Antineoplastic Agents; Body Weight; Fluorouracil; Glycine; Leukemia L | 1992 |
[Effect of UFT with high dose leucovorin for transplantable bladder tumor (MBT-2) in mice].
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Body Weight; Drug Synergism; Leucovorin; Mi | 1991 |
The effect of UFTM therapy on primary and metastatic colon cancer from the same human xenotransplanted into nude mice.
Topics: Adenocarcinoma, Mucinous; Animals; Antineoplastic Combined Chemotherapy Protocols; Body Weight; Colo | 1990 |
[Antitumor activity and toxicity to the immune system and intestine, of the fluorinated pyrimidines FUra, 5'-DFUR, tegafur and UFT].
Topics: Animals; Antibody Formation; Antineoplastic Combined Chemotherapy Protocols; Body Weight; Bone Marro | 1988 |
The antiproliferative effects of fluoropyrimidine derivatives against human tumor xenografts in a subrenal capsule assay.
Topics: Animals; Antineoplastic Agents; Body Weight; Cell Division; Colorectal Neoplasms; Floxuridine; Fluor | 1988 |
[Experimental study of UFT in prostatic carcinoma (DU-145) in nude mice].
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Body Weight; Cell Line; Cells, Cultured; Hu | 1986 |
[In vivo chemosensitivity test for UFT and FT-207. I--Subrenal capsule assay].
Topics: Adenocarcinoma; Animals; Antineoplastic Combined Chemotherapy Protocols; Body Weight; Colonic Neopla | 1987 |
[UFT therapy of experimental gastric cancer in beagles induced by ENNG].
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Body Weight; Dogs; Male; Methylnitronitroso | 1987 |
[Antitumor effect of intermittent oral administration of UFT against human rectal cancer xenografted in nude mice].
Topics: Administration, Oral; Animals; Antineoplastic Combined Chemotherapy Protocols; Body Weight; Drug Adm | 1988 |
[Effect of combined BCG and UFT therapy of human maxillary cancer transplanted into nude mice].
Topics: Administration, Oral; Animals; Antineoplastic Combined Chemotherapy Protocols; BCG Vaccine; Body Wei | 1988 |
Longer survival and fewer metastases by levamisole and tegafur in 1, 2-dimethylhydrazine-induced murine colonic cancers.
Topics: 1,2-Dimethylhydrazine; Animals; Antineoplastic Combined Chemotherapy Protocols; Body Weight; Colonic | 1985 |